Welcome to our dedicated page for YS Biopharma Co SEC filings (Ticker: YSBPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
YS Biopharma Co. Ltd. filings document LakeShore Biopharma as a foreign private issuer reporting on Form 6-K and Form 20-F status. The records include current reports covering financial results, private placement financing, ordinary share and warrant transactions, change-in-control disclosure, and incorporation by reference into Form S-8 registration statements.
The filings also cover governance processes, including special committee matters and the engagement of independent financial and legal advisers. For YSBPW, the disclosure record centers on warrant-related capital structure, ordinary share issuance, foreign-issuer reporting obligations, and material corporate events.
LakeShore Biopharma Co., Ltd. submitted a foreign issuer report describing a recent corporate governance step. The company furnished a press release as an exhibit stating that it has appointed an independent financial advisor and legal counsel to its special committee. The report is signed by Director and Chief Financial Officer Rachel Yu.
LakeShore Biopharma Co., Ltd. filed a report noting that it received a revised preliminary, non-binding proposal to acquire the company. This kind of proposal is an early-stage takeover interest rather than a finalized deal.
The board has formed a special committee to evaluate the proposal. A special committee typically consists of independent directors who review potential transactions and consider what is in the best interests of shareholders before any decision is made.
Amendment to Schedule 13D reporting that a consortium led by Oceanpine Investment, Oceanpine Capital and Crystal Investment has proposed a potential acquisition of all outstanding ordinary shares of LakeShore Biopharma Co., Ltd. The Revised Proposal values each ordinary share at US$0.86 in cash. Crystal Investment currently holds 21,021,332 shares (51.0%) based on 41,212,693 shares outstanding as of June 30, 2025. Oceanpine-held positions total 462,760 shares (1.1%), comprising 410,560 held by Oceanpine Investment and 52,200 by Oceanpine Capital.
The Consortium entered a Consortium Agreement providing for cooperative negotiation, exclusive collaboration among members for up to 24 months, and anticipated contributions of cash or shares to an acquisition vehicle. The Reporting Persons estimate approximately US$20,000,000 will be expended to acquire the publicly held shares at the Revised Proposal price. If consummated, the Proposed Transaction could result in delisting and termination of registration of the Ordinary Shares.
LakeShore Biopharma Co., Ltd submitted a Form 6-K reporting that it has issued a press release about receiving a preliminary, non-binding proposal to acquire the company. The filing itself does not include the proposal terms, but it confirms that an acquisition approach has been made and that details are described in an attached press release.
LakeShore Biopharma Co., Ltd. (Nasdaq: LSB / LSBPW) filed its FY 2025 Form 20-F covering the 12 months ended 31 Mar 2025.
- Scale & Structure: 20.77 m ordinary shares outstanding; Cayman-incorporated holding company with substantial PRC operations conducted through wholly-owned subsidiaries such as Beijing Yisheng and Liaoning Yisheng.
- Financials: FY25 net loss of RMB100 m (US$13.9 m), bringing accumulated deficit to US$335 m. Cash on hand RMB107.5 m (US$15 m) versus loans/borrowings of RMB413.9 m (US$57.7 m). Auditor Grant Thornton Zhitong issued a going-concern warning.
- Revenue Mix: 100 % of revenue still derives from its single commercial product, the rabies vaccine YSJA™; pipeline assets (e.g., accelerated-dose PIKA rabies vaccine, PIKA YS-ON-001 immuno-oncology candidate) remain in clinical/pre-clinical stages.
- Key Risks: heavy dependence on one product, intense vaccine competition, sizable cash burn, high leverage, and possible HFCAA-related delisting if PCAOB access lapses. Company faces extensive PRC regulatory, currency-transfer and data-security constraints.
- Regulatory Status: Emerging-growth, non-accelerated filer; U.S. GAAP reporter; no internal-control audit under SOX 404(b).
Overall, the filing underscores liquidity pressure, strategic reliance on rabies franchise, and heightened geopolitical/regulatory headwinds that may impair future financing and market access.
Schedule 13D discloses that Crystal Peak Investment Inc., its parent Crystal Peak Holdings Inc. and sole shareholder/director Huaqin Xue have become controlling shareholders of LakeShore Biopharma Co., Ltd. ("LakeShore"). On 8 Jul 2025 the parties executed a Share & Warrant Purchase Agreement under which Crystal Investment bought 16,987,542 ordinary shares at US$0.883 each (US$15 m cash) and received an equal number of warrants exercisable at US$1.079. All warrants were cashlessly exercised on 11 Jul 2025 for 4,033,790 additional shares, taking the group’s total holding to 21,021,332 shares, or 51.0 % of the 41,212,693 shares outstanding.
The proceeds must be used for operations, expansion of LakeShore’s core business and working-capital needs; any other use requires Crystal Investment’s written consent, giving the new owner de-facto oversight of capital allocation. The acquisition was made for investment purposes, but the filing states the group may buy or sell additional securities depending on price, strategy and market conditions.
The transaction provides immediate liquidity to LakeShore and introduces a single majority owner, signalling potential strategic direction changes, governance realignment and future capital market activity. No criminal or civil proceedings involving the reporting persons were disclosed.